cetylpyridinium chloride + chlorocresol + lidocaine hydrochloride: clinical use

Prescribing considerations

• Confirm that the formulation is licensed for the indication and age group; adult-strength gel is unsuitable for teething.
• For teething, recommend non-pharmacological measures first and provide pharmacist guidance.
• Avoid concurrent lidocaine products and consider medicines that increase lidocaine exposure or cardiac effects.
• Use cautiously on wounded or traumatised mucosa because systemic absorption may increase.
• Consider cumulative ethanol or propylene-glycol exposure in young children.

Contraindications and cautions

• Hypersensitivity to an active ingredient, amide-type local anaesthetic or formulation excipient
• Porphyria
• Adult-strength gel in children under 12 years

Monitoring

• Routine laboratory monitoring is not required for appropriate short-term local use.
• Assess persistent or worsening oral lesions rather than continuing repeated symptomatic treatment.
• After excessive exposure, assess neurological, respiratory and cardiovascular status; obtain an ECG when toxicity is suspected.

Clinical pharmacology

Lidocaine reversibly inhibits nerve-impulse generation and transmission. It is absorbed across oral mucosa, especially when damaged, and undergoes extensive hepatic first-pass metabolism. Chlorocresol and cetylpyridinium chloride act locally as antiseptics.

Formulation and product differences

• Liquid contains menthol and is licensed for mouth ulcers, denture irritation and selected teething use.
• Teething gel is licensed from 5 months for teething after non-medicine measures fail, and for mouth ulcers and denture irritation.
• Adult-strength gel has a higher lidocaine concentration, is restricted to people aged 12 years and over, and is unsuitable for teething.
• Both gels contain clove oil; all three selected formulations contain ethanol.